Recreational drug use has been a part of most cultures for millennia. No surprise then that modern generations still want to get high, despite how much criminal legislation is passed to discourage them from doing so. So-called ‘designer drugs’ – also known until recently as ‘legal highs’ – are just the latest to come under legal scrutiny, but are the new laws working
Articles: 29.02 February 2018
Although there is no curative treatment for genital herpes, antiviral therapy can reduce the duration of symptoms and the frequency and severity of recurrences. This article discusses the diagnosis of genital herpes, the treatment options available and the GP’s role in management
It is now recognised that oral NSAIDs can increase the risk of cardiovascular events, including myocardial infarction and stroke. This article discusses the potential mechanisms involved and how the risk can be minimised
Health professionals are increasingly making use of digital technology such as healthcare apps to improve patient outcomes. Here, the authors discuss the findings of their discovery project to investigate whether community pharmacists can successfully promote patient self-care using the Simple Florence text messaging system and the Manage Your Health app.
In July 2017, NICE updated its 2006 guideline on Parkinson’s disease in adults, with major revisions to its recommendations on pharmacological and non-pharmacological management of motor and non-motor symptoms. This article provides a summary of the new guidance
The British Society for Rheumatology and British Health Professionals in Rheumatology recently updated their guidance on prescribing and monitoring non-biological disease-modifying antirheumatic drugs (DMARDs) for patients with rheumatic disease. This article provides an overview of the main recommendations of the new guideline
In 2016, the Psychoactive Substances Act came into force to address increasing concerns about the use of new psychoactive substances, also known as designer drugs or ‘legal highs’. In this article, the author discusses how big the problem of designer drugs is, and what impact the new Act is likely to have on their production.
Cladribine (Mavenclad) is a new oral treatment for adults with highly active relapsing multiple sclerosis. This article summarises its dosing and monitoring requirements, efficacy in the CLARITY trial and place in therapy